After suspending the clinical trials of Covaxin following the termination of Bharat Biotech’s MoU with its Brazilian partner Precisa Medicamentos, Brazil’s health regulator Anvisa (Agencia Nacional de Vigilancia Sanitaria) has now closed the emergency use authorisation (EUA) request for the Indian vaccine as well.
